Friday, July 10, 2026
🇺🇸 FDA

pharma · Obesity, Overweight · Type 2 Diabetes

Eli Lilly and

Eli Lilly Co.

Eli Lilly and drug portfolio — 99 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
Lilly Corporate Center, Indianapolis, Indiana 46285, US HQ
1876 Founded
55,860 Employees
EMA registrant Type
Company details
Status
Public
HQ
Lilly Corporate Center, Indianapolis, Indiana 46285, US
Founded
1876
Employees
55,860
Programs
107
Drugs
99
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Drug Pipeline

Eli Lilly and pipeline

Portfolio lens on 99 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Eli Lilly and drug portfolio — 99 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

99 compounds

  1. abemaciclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.

    Target
    Cyclin-dependent kinase 4
    Mechanism
    Cyclin-dependent kinase 6 inhibitor

  2. abiraterone

    Antineoplastic and immunomodulating agents (L02)

    Antineoplastic and immunomodulating agents (L02) compound in Eli Lilly and's portfolio. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Steroid 5-alpha-reductase inhibitor

  3. acetaminophen

    US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Cyclooxygenase inhibitor

  4. acyclovir sodium

    US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.

    Target
    DNA polymerase catalytic subunit
    Mechanism
    Human herpesvirus 1 DNA polymerase inhibitor

  5. adalimumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  6. administered

    Development asset linked to Eli Lilly and in public FDA and regional records.

  7. alcohol

    US regulatory status: approved.

  9. alzheimer

    Development asset linked to Eli Lilly and in public FDA and regional records.

  10. anastrozole

    US regulatory status: approved. Molecular target: Aromatase.

    Target
    Aromatase
    Mechanism
    Cytochrome P450 19A1 inhibitor

  11. anti-

    Development asset linked to Eli Lilly and in public FDA and regional records.

  12. antibody

    Development asset linked to Eli Lilly and in public FDA and regional records.

  13. aprepitant

    Alimentary tract and metabolism (A04)

    US regulatory status: approved. Molecular target: Substance-P receptor.

    Target
    Substance-P receptor
    Mechanism
    Neurokinin 1 receptor antagonist

  15. baricitinib

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase JAK1.

    Target
    Tyrosine-protein kinase JAK1
    Mechanism
    Tyrosine-protein kinase JAK2 inhibitor

  16. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  17. cabozantinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Mechanism: Hepatocyte growth factor receptor inhibitor.

    Mechanism
    Hepatocyte growth factor receptor inhibitor

  18. capsule

    Development asset linked to Eli Lilly and in public FDA and regional records.

  19. capsules

    Development asset linked to Eli Lilly and in public FDA and regional records.

  20. carboplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  21. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  22. cend-

    Development asset linked to Eli Lilly and in public FDA and regional records.

  23. cetuximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  24. chloride

    Development asset linked to Eli Lilly and in public FDA and regional records.

  25. cisplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  26. combination

    Development asset linked to Eli Lilly and in public FDA and regional records.

  28. cortisone

    Development asset linked to Eli Lilly and in public FDA and regional records.

  29. dapagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  30. darolutamide

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  31. dexamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  32. donanemab

    Nervous system (N06)

    Nervous system (N06) compound in Eli Lilly and's portfolio. Molecular target: Amyloid-beta precursor protein.

    Target
    Amyloid-beta precursor protein
    Mechanism
    Beta amyloid A4 protein disrupting agent

  33. doxorubicin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Eli Lilly and's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  34. dulaglutide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.

    Target
    Glucagon-like peptide 1 receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  35. durvalumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  36. eloralintide

    Development asset linked to Eli Lilly and in public FDA and regional records.

  37. empagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  38. enfortumab

    Development asset linked to Eli Lilly and in public FDA and regional records.

  39. enfortumab vedotin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Eli Lilly and's portfolio. Molecular target: Nectin-4.

    Target
    Nectin-4
    Mechanism
    Tubulin inhibitor

  40. erlotinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Eli Lilly and's portfolio. Mechanism: Epidermal growth factor receptor erbB1 inhibitor.

    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  41. etanercept

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  42. exemestane

    US regulatory status: approved. Molecular target: Aromatase.

    Target
    Aromatase
    Mechanism
    Cytochrome P450 19A1 inhibitor

  43. florbetapir (18f)

    Various (V09)

    Various (V09) compound in Eli Lilly and's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  44. flortaucipir (18f)

    Various (V09)

    Various (V09) compound in Eli Lilly and's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  45. fluconazole

    US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.

    Target
    Lanosterol 14-alpha demethylase
    Mechanism
    Cytochrome P450 51 inhibitor

  46. fulvestrant

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor antagonist

  47. galcanezumab

    Nervous system (N02)

    Nervous system (N02) compound in Eli Lilly and's portfolio. Molecular target: Calcitonin gene-related peptide.

    Target
    Calcitonin gene-related peptide
    Mechanism
    Calcitonin gene-related peptide inhibitor

  48. gemcitabine

    US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.

    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  49. glargine

    Development asset linked to Eli Lilly and in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  50. granisetron

    Alimentary tract and metabolism (A04)

    US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.

    Target
    5-hydroxytryptamine receptor 3A
    Mechanism
    Serotonin 3a (5-HT3a) receptor antagonist

  51. hema-

    Development asset linked to Eli Lilly and in public FDA and regional records.

  52. hydrocortisone

    Systemic hormonal preparations (H02)

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  53. infusion

    Development asset linked to Eli Lilly and in public FDA and regional records.

  54. inhibitor

    Development asset linked to Eli Lilly and in public FDA and regional records.

  55. injection

    Development asset linked to Eli Lilly and in public FDA and regional records.

  56. insulin

    Development asset linked to Eli Lilly and in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  57. insulin glargine

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  58. iohexol

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  59. irinotecan

    Development asset linked to Eli Lilly and in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.

    Mechanism
    DNA topoisomerase I inhibitor

  60. lasmiditan

    Nervous system (N02)

    US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 1F.

    Target
    5-hydroxytryptamine receptor 1F
    Mechanism
    Serotonin 1f (5-HT1f) receptor agonist

  61. lebrikizumab

    Dermatologicals (D11)

    Dermatologicals (D11) compound in Eli Lilly and's portfolio. Molecular target: Interleukin-13.

    Target
    Interleukin-13
    Mechanism
    Interleukin-13 inhibitor

  62. letrozole

    US regulatory status: approved. Molecular target: Aromatase.

    Target
    Aromatase
    Mechanism
    Cytochrome P450 19A1 inhibitor

  63. ly3209590

    Development asset linked to Eli Lilly and in public FDA and regional records.

  64. ly3484356

    Development asset linked to Eli Lilly and in public FDA and regional records.

  65. metformin

    Development asset linked to Eli Lilly and in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.

    Mechanism
    Mitochondrial complex I (NADH dehydrogenase) inhibitor

  66. mirikizumab

    Antineoplastic and immunomodulating agents (L04)

    Antineoplastic and immunomodulating agents (L04) compound in Eli Lilly and's portfolio. Molecular target: Interleukin-23.

    Target
    Interleukin-23
    Mechanism
    Interleukin-23 inhibitor

  67. mirvetuximab

    Development asset linked to Eli Lilly and in public FDA and regional records. Molecular target: Folate receptor alpha.

    Target
    Folate receptor alpha
    Mechanism
    Folate receptor alpha binding agent

  68. mirvetuximab soravtansine

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Eli Lilly and's portfolio. Molecular target: Folate receptor alpha.

    Target
    Folate receptor alpha
    Mechanism
    Tubulin inhibitor

  69. mometasone

    Development asset linked to Eli Lilly and in public FDA and regional records.

  70. normal

    Development asset linked to Eli Lilly and in public FDA and regional records.

  71. ondansetron

    US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.

    Target
    5-hydroxytryptamine receptor 3A
    Mechanism
    Serotonin 3a (5-HT3a) receptor antagonist

  72. orforglipron

    Development asset linked to Eli Lilly and in public FDA and regional records.

  73. paclitaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  74. palbociclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: CDK6/cyclin D1.

    Target
    CDK6/cyclin D1
    Mechanism
    Cyclin-dependent kinase 4/cyclin D1 inhibitor

  75. palonosetron

    Alimentary tract and metabolism (A04)

    Alimentary tract and metabolism (A04) compound in Eli Lilly and's portfolio. Mechanism: Serotonin 3a (5-HT3a) receptor antagonist.

    Mechanism
    Serotonin 3a (5-HT3a) receptor antagonist

  76. pembrolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  77. pemetrexed sodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  78. peritoneal

    Development asset linked to Eli Lilly and in public FDA and regional records.

  79. pirtobrutinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  80. placebo

    Development asset linked to Eli Lilly and in public FDA and regional records.

  81. prednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  82. prednisone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  83. ramucirumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor 2.

    Target
    Vascular endothelial growth factor receptor 2
    Mechanism
    Vascular endothelial growth factor receptor 2 inhibitor

  84. ribociclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.

    Target
    Cyclin-dependent kinase 4
    Mechanism
    Cyclin-dependent kinase 6 inhibitor

  85. selpercatinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET.

    Target
    Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET
    Mechanism
    Tyrosine-protein kinase receptor RET inhibitor

  87. solution

    Development asset linked to Eli Lilly and in public FDA and regional records.

  88. suspension

    Development asset linked to Eli Lilly and in public FDA and regional records.

  89. tablet

    Development asset linked to Eli Lilly and in public FDA and regional records.

  90. tablets

    Development asset linked to Eli Lilly and in public FDA and regional records.

  91. tamoxifen

    Development asset linked to Eli Lilly and in public FDA and regional records. Mechanism: Estrogen receptor alpha modulator.

    Mechanism
    Estrogen receptor alpha modulator

  92. temozolomide

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  93. tirzepatide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Gastric inhibitory polypeptide receptor.

    Target
    Gastric inhibitory polypeptide receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  94. tocilizumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.

    Target
    Interleukin-6 receptor subunit alpha
    Mechanism
    Interleukin-6 receptor alpha subunit inhibitor

  95. topotecan hydrochloride

    US regulatory status: approved. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I, mitochondrial inhibitor

  96. treatment

    Development asset linked to Eli Lilly and in public FDA and regional records.

  97. triamcinolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  98. triamcinolone acetonide

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  99. vandetanib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Ephrin receptor.

    Target
    Ephrin receptor
    Mechanism
    Ephrin receptor inhibitor

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.